Related Experiment Video
Updated: Oct 6, 2025
Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
Published on: September 23, 2022
The Molecular Mechanisms Through Which Placental Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Myelin
Kaitlin C Clark1, David Wang1, Priyadarsini Kumar1
1UC Davis Health: Department of Surgery, 4625 2nd Ave., Research II, Room 3101, Sacramento, CA, 95817, USA.
Abstract:
Multiple sclerosis (MS) is a debilitating degenerative disease characterized by an immunological attack on the myelin sheath leading to demyelination and axon degeneration. Mesenchymal stem/stromal cells (MSCs) and secreted extracellular vesicles (EVs) have become attractive targets as therapies to treat neurodegenerative diseases such as MS due to their potent immunomodulatory and regenerative properties. The placenta is a unique source of MSCs (PMSCs), demonstrates "fetomaternal" tolerance during pregnancy, and serves as a novel source of MSCs for the treatment of neurodegenerative diseases. PMSCs and PMSC-EVs have been shown to promote remyelination in animal models of MS, however, the molecular mechanisms by which modulation of autoimmunity and promotion of myelination occurs have not been well elucidated. The current review will address the molecular mechanisms by which PMSC-EVs can promote remyelination in MS.
Insights
Placenta-derived mesenchymal stem/stromal cells (PMSCs) and their extracellular vesicles (EVs) show promise for treating multiple sclerosis (MS). This review explores how these placental stem cell-derived EVs promote myelin repair and reduce autoimmune attacks in MS.
Area of Science:
- Neuroimmunology
- Regenerative Medicine
- Cell Biology
Background:
- Multiple sclerosis (MS) is a neurodegenerative disease involving myelin damage and axon loss.
- Mesenchymal stem/stromal cells (MSCs) and extracellular vesicles (EVs) offer therapeutic potential for MS due to immunomodulatory and regenerative effects.
- Placenta-derived MSCs (PMSCs) are a unique source with potential for treating neurodegenerative conditions.
Purpose of the Study:
- To review the molecular mechanisms underlying the therapeutic effects of PMSC-EVs in MS.
- To elucidate how PMSC-EVs modulate autoimmunity and promote remyelination in MS models.
Main Methods:
- Review of existing literature on PMSCs, PMSC-EVs, and their effects in MS models.
- Analysis of molecular pathways involved in immunomodulation and remyelination.
Main Results:
- PMSCs and PMSC-EVs demonstrate efficacy in promoting remyelination in animal models of MS.
- Evidence suggests PMSC-EVs can modulate autoimmune responses contributing to MS pathology.
Conclusions:
- PMSC-EVs represent a promising cell-free therapy for MS.
- Further research into the specific molecular mechanisms of PMSC-EVs is crucial for clinical translation.
